Tdap for Pregnant Women: Information for Providers
For Health Care Professionals
Pregnant women should receive a dose of Tdap during each pregnancy between 27 and 36 weeks gestation.
In October 2012, the Advisory Committee on Immunization Practices (ACIP) voted to recommend that health care personnel should administer a dose of Tdap during each pregnancy irrespective of the patient's prior history of receiving Tdap (or Td). To maximize the maternal antibody response and passive antibody transfer to the infant, optimal timing for Tdap administration is between 27 and 36 weeks gestation. This recommendation is supported by the American College of Obstetricians and Gynecologists (ACOG).
In 2012, 48,277 cases of pertussis were reported in the United States; 2,269 of those cases were in infants younger than 3 months of age — 15 of those infants died. Studies have shown that when the source of pertussis was identified, mothers were responsible for 30–40% of infant infections.
Pertussis can cause serious and sometimes life-threatening complications in infants, especially within the first 6 months of life. In infants younger than 1 year of age who get pertussis, about half are hospitalized. The younger the infant, the more likely treatment in the hospital will be needed. Of those infants who are hospitalized with pertussis, about 67% will have apnea, 23% will get pneumonia, and 1.6% will die.
Adolescents and adults can also experience complications from pertussis. Complications are usually less serious in this age group, especially in those who have been vaccinated. Common complications in adolescents and adults are often caused by the cough itself, including urinary incontinence (28%), syncope (6%), and rib fractures (4%).
It's expected that vaccinating your patients with Tdap during pregnancy will prevent more infant hospitalizations and deaths from pertussis than "cocooning" alone.
Visit ACOG's Pertussis Information for Ob/Gyns website for provider FAQs, a Tdap Toolkit, and other resources to promote Tdap vaccination in pregnancy.
Three key strategies are recommended to protect infants from pertussis:
- Administering Tdap vaccine to women during every pregnancy
- Encouraging close contacts of infants to be up-to-date with their pertussis vaccine (cocooning)
- Vaccinating infants with DTaP according to the childhood immunization schedule
Transfer of Pertussis Antibodies to Infant through Maternal Tdap Vaccination
The level of pertussis antibodies decreases over time, so Tdap vaccine should be administered during every pregnancy so that each infant receives high levels of protective antibodies.
Transplacental transfer of maternal pertussis antibodies from mother to infant provides some protection against pertussis in early life, before infants are able to receive the primary DTaP series. Since the immune response to the vaccine peaks about 2 weeks after administration, Tdap vaccine is recommended between 27 and 36 weeks gestation in order to optimize antibody transfer and protection at birth. The level of pertussis antibodies decreases over time, so Tdap vaccine should be administered during every pregnancy so that each infant receives high levels of protective antibodies.
The effectiveness of maternal antibodies in preventing infant pertussis is not yet known, but pertussis antibodies can protect against some disease and the severe outcomes that come along with it. Experts believe that vaccinating your patients with Tdap during pregnancy will prevent more infant hospitalizations and deaths from pertussis than "cocooning" alone.
Vaccination with Tdap during pregnancy is ideal. Public health professionals expect that administering Tdap during pregnancy will prevent more infant hospitalizations and deaths from pertussis than postpartum vaccination. However, if a woman does not get vaccinated during pregnancy and has never received Tdap before, administer the vaccine immediately postpartum, before she leaves the hospital or birthing center. Also advise your patient that other adults who will be around her newborn, such as dads, grandparents, older siblings, and babysitters, should also be up-to-date with their pertussis vaccine.
There are currently no pertussis vaccines licensed or recommended for newborns at birth. The best way to prevent pertussis in a young infant is by vaccinating the mother during pregnancy, encouraging people around the infant to be up-to-date with their pertussis vaccine, and administering the childhood DTaP series on schedule.
Both CDC and FDA monitor vaccine safety through the Vaccine Adverse Event Reporting System (VAERS), a national vaccine safety surveillance program. Published studies that include VAERS data support the safe use of Tdap vaccine during pregnancy. To date, no safety signals have been found among pregnant women or their babies after Tdap vaccination.
Both tetanus and diphtheria toxoids (Td) and tetanus toxoid (TT) vaccines have been used extensively in pregnant women worldwide since the 1960s to prevent neonatal tetanus. Td and TT vaccines administered during pregnancy have not been shown to harm either the mother or baby/fetus.
See the Pregnancy and Whooping Cough Research page for a list of published articles specific to preventing pertussis in infants, including safety studies.
Most side effects from Tdap vaccination are mild or moderate, and self-resolving. The most common side effects include erythema, swelling, pain, and tenderness at the injection site, body-ache, fatigue, or fever. Severe side effects are extremely rare, especially in adults.
CDC and ACOG consider the benefits of Tdap vaccination in multiple pregnancies to outweigh the theoretical risk for severe hypersensitivity due to administering the tetanus component of the Tdap vaccine more often (see ACOG's Committee Opinion). Studies found that adults who receive 2 tetanus shots in a short period of time (within 2 years) were no more likely than adults getting their first Tdap vaccine to have severe side effects. Experts believe the risk for this type of severe side effect has likely been reduced since these vaccines are now made with lower doses of the tetanus component than tetanus vaccines in the past.
Breastfeeding is not a contraindication for receiving Tdap vaccine and is, in fact, fully compatible with Tdap vaccination. Tdap vaccine can and should be given to women who plan to breastfeed.
Pertussis and flu vaccines can safely be coadministered to pregnant women. Pregnant women should receive the flu vaccine as early as possible in the flu season, during any trimester, while the pertussis vaccine is recommended later in pregnancy (between 27 and 36 weeks gestation).
None of the pertussis vaccines (Tdap and DTaP) currently used in the United States contain thimerosal.
By vaccinating a woman with Tdap during pregnancy her infant will gain pertussis antibodies during the most vulnerable time – before 3 months of age. However, providing this early immunity may also interfere with the infant's immune response to DTaP vaccine. The infant's immune response to DTaP may not be as strong, but the clinical implications may not be significant. Researchers are still working to understand this issue.
However, the benefits of vaccinating during pregnancy and protecting a newborn outweigh the potential risk of blunting the infant's response to DTaP vaccine. Since infants are at greatest risk of severe disease and death from pertussis before 3 months of age – when their immune systems are least developed – any protection that can be provided is critical. Infants should receive their DTaP vaccines on schedule, starting at 2 months of age.
CDC's current estimate is that Tdap vaccination protects against pertussis in about 70% of people who receive it, but that protection fades over time. The long-term effectiveness of Tdap is still being studied.
Adolescents and adults who get Tdap and still get pertussis have fewer coughing fits, shorter illness, and are less likely to suffer from disease complications. Since pregnant women pass some protection to their infants through transplacental transfer of maternal antibodies, their infants also have some protection against the severe outcomes that come with this disease. Studies are ongoing to learn how long maternal antibodies provide protection to infants. That is why it is critical that infants receive the childhood DTaP series on schedule so protection is maintained throughout childhood.
DTaP vaccination is effective for 80%–90% of children who receive it. Among children who get all 5 doses of DTaP vaccine on schedule, effectiveness is very high within the year following the 5th dose — nearly all children (98%) are fully protected. More is known about the long-term effectiveness of DTaP. In general, there is a modest decrease in effectiveness in each year following the last dose. About 70% of children are fully protected 5 years after getting their last dose of DTaP and the other 30% are protected against serious disease.
In addition to vaccinating your patients with Tdap, you should educate them about encouraging others – including dads, grandparents and other caregivers – to be up-to-date with pertussis vaccination.
The strategy of protecting infants from pertussis by vaccinating those in close contact with them is known as "cocooning." ACIP has recommended cocooning with Tdap vaccine since 2005 and continues to recommend this strategy for all those with expected close contact with infants younger than 1 year of age. Cocooning, in combination with maternal Tdap vaccination and administering the childhood DTaP series on schedule, provides the best protection to the infant.
In addition to vaccinating your patients with Tdap, you should educate them about encouraging others – including dads, grandparents and other caregivers – to be up-to-date with pertussis vaccination. For family members who aren't up-to-date with Tdap vaccine, they should get vaccinated at least 2 weeks before coming into contact with the infant.
Full implementation of cocooning has proven to be a challenge; vaccinating during pregnancy provides the best opportunity to protect very young infants from pertussis.
It is very important for infants to get their own pertussis vaccine (DTaP) according to the childhood schedule so they can start building their own protection against the disease. The primary series is administered at 2, 4, and 6 months to build up high levels of protection. Booster shots are administered at 15 through 18 months and at 4 through 6 years to maintain that protection.
See the Pregnancy and Whooping Cough Research page for a list of published articles specific to preventing pertussis in infants, including safety studies and immunization recommendations.
Images and logos on this website which are trademarked/copyrighted or used with permission of the trademark/copyright or logo holder are not in the public domain. These images and logos have been licensed for or used with permission in the materials provided on this website. The materials in the form presented on this website may be used without seeking further permission. Any other use of trademarked/copyrighted images or logos requires permission from the trademark/copyright holder...more
This graphic notice means that you are leaving an HHS Web site. For more information, please see the Exit Notification and Disclaimer policy.